Literature DB >> 10584998

Reversible peritoneal calcification in a patient treated by CAPD.

C Kitoh1, K Miyagi, T Onoe, K Katano, T Shimada, T Takegoshi.   

Abstract

The patient, a female, aged 65 years, developed diffuse peritoneal calcification nine years after commencing CAPD therapy. No abdominal symptoms or evidence of peritonitis were discovered during this period. Before peritoneal calcification was detected, a dialysate with a high glucose concentration (3.86%) had been used once daily for 16 months. In the case of this patient, it was not possible to discover any of the previous indicated etiologies of peritoneal calcification such as significantly elevated values for the product Ca x P, overt secondary hyperparathyroidism, or relapsing peritonitis. It was realized that the use of a high-glucose dialysate in a patient on long-term CAPD treatment had been one causative factor. After peritoneal calcification had been confirmed, the calcium concentration of the dialysate changed from 3.5 mEq/l to 2.5 mEq/l and the patient was put on a regime of 2.0 g alumigel (aluminum-containing phosphate binders) a day. Eight months later, a CT scan was taken. The peritoneal calcification has clearly been mitigated. At present, CAPD therapy is being continued in the absence of any abdominal symptoms.

Entities:  

Mesh:

Year:  1999        PMID: 10584998

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  A Rare Case of Extensive Eggshell Intestinal Wall Peritoneal Calcification in a Long-Term Continuous Peritoneal Dialysis Patient.

Authors:  Erasmia Sampani; Chrysostomos Dimitriadis; Efstratios Kasimatis; Evangelos Memmos; Aikaterini Papagianni
Journal:  Case Rep Nephrol       Date:  2022-09-26

2.  High peritoneal KT/V and peritonitis rates are associated with peritoneal calcification.

Authors:  Jenq-Wen Huang; Yu-Chung Lien; Chung-Yi Yang; Kao-Lang Liu; Cheng-Chung Fang; Cho-Kai Wu; Jen-Kuang Lee; Hon-Yen Wu; Chih-Kang Chiang; Hui-Teng Cheng; Chung-Jen Yen; Kuan-Yu Hung
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.